C3i Center vs Green Phoenix Labs: CDMO Comparison
How does C3i Center compare to Green Phoenix Labs for Cell Therapy manufacturing?
Side-by-side comparison of C3i Center and Green Phoenix Labs on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Green Phoenix Labs holds 1 active EMA GMP certificates; C3i Center does not appear in EudraGMDP.
- Composite Signal Score: Green Phoenix Labs 78/100 vs C3i Center 59/100 — a 19-point gap reflecting the combined quality, capacity and financial signal.
On a 13-modality CDMO landscape, both C3i Center and Green Phoenix Labs qualify as Cell Therapy manufacturers; Green Phoenix Labs carries the higher composite Signal Score for Cell Therapy programs in this comparison.
What to evaluate for Cell Therapy programs
Both C3i Center and Green Phoenix Labs qualify as Cell Therapy CDMOs. When choosing between them for Cell Therapy programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Autologous vs allogeneic
Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.
Vector & raw materials
Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.
Closed-system & cleanrooms
Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.
Cold chain & logistics
Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.
Frequently asked: C3i Center vs Green Phoenix Labs
How does C3i Center compare to Green Phoenix Labs for Cell Therapy manufacturing?
On CDMO Signal's composite Signal Score, C3i Center is 59/100 and Green Phoenix Labs is 78/100; European coverage is 0 active EMA+MHRA certificates for C3i Center vs 1 for Green Phoenix Labs. Both are tracked in the CDMO Signal directory as Cell Therapy CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
How do C3i Center and Green Phoenix Labs compare on European GMP coverage?
C3i Center holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Green Phoenix Labs holds 1 active EMA GMP certificate and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for Cell Therapy manufacturing — C3i Center or Green Phoenix Labs?
Both C3i Center and Green Phoenix Labs are tagged as Cell Therapy CDMOs in our directory, so both are credible options for Cell Therapy programs. The most important differentiator for Cell Therapy selection is typically autologous vs allogeneic: Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
C3i Center carries a Signal Score of 59/100 and Green Phoenix Labs carries 78/100 — a meaningful lead for Green Phoenix Labs. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →